Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Akebia Therapeutics Inc.

    NASDAQ: AKBA · Real-Time Price · USD
    3.23
    0.20 (6.60%)
    At close: Jun 02, 2025, 2:24 PM
    6.60%
    Bid 3.22
    Market Cap 847M
    Revenue (ttm) 184.91M
    Net Income (ttm) -45.31M
    EPS (ttm) -0.21
    PE Ratio (ttm) -15.36
    Forward PE 150.75
    Analyst Buy
    Ask 3.23
    Volume 5,719,895
    Avg. Volume (20D) 5,167,198
    Open 3.06
    Previous Close 3.03
    Day's Range 2.97 - 3.23
    52-Week Range 0.80 - 3.23
    Beta 0.88

    About AKBA

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol AKBA
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for AKBA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    3 weeks ago
    +6.5%
    Akebia Therapeutics shares are trading higher afte... Unlock content with Pro Subscription
    2 months ago
    -28.17%
    Akebia Therapeutics shares are trading lower after the company announced the pricing of a $50 million offering of 25 million common shares at $2/share.
    news image

    3 weeks ago · seekingalpha.com

    Akebia Therapeutics, Inc. (AKBA) Q1 2025 Earnings Call Transcript

    Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director of Investor Relations John Butler - Chief Exec...

    news image

    3 weeks ago · zacks.com

    Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates

    Akebia Therapeutics (AKBA) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.09 per share a year ago.

    news image

    1 month ago · zacks.com

    Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy?

    Akebia Therapeutics (AKBA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    news image

    1 month ago · zacks.com

    Why You Shouldn't Bet Against Akebia Therapeutics (AKBA) Stock

    Akebia Therapeutics (AKBA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

    news image

    2 months ago · zacks.com

    Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering

    AKBA's shares fell after announcing the pricing of its secondary issue of shares, which were at a discount to the previous closing price.

    news image

    2 months ago · benzinga.com

    JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

    U.S. stock futures were lower this morning, with the Dow futures falling around 200 points on Thursday.

    news image

    2 months ago · seekingalpha.com

    Akebia Therapeutics, Inc. (AKBA) Q4 2024 Earnings Call Transcript

    Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q4 2024 Earnings Conference Call March 13, 2025 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director, IR John Butler - CEO Nick Grund - Chief Co...

    news image

    2 months ago · zacks.com

    Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates

    Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to break-even earnings per share a year ago.

    Add to Watchlist